Jun 30, 2020
Mezzion Announces Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients who have undergone the Fontan Operation for Single Ventricle Heart Disease
May 18, 2020
Mezzion Pharma's new orphan drug udenafil improved ventricular function measured by myocardial performance index (MPI) in adolescents with congenital single ventricle heart disease (SVHD) - Further results from the pivotal 400-subject Phase 3 FUEL Trial
Jan 09, 2020
The American Heart Association ("AHA") Recognizes Mezzion's FUEL Trial as the Biggest Victory in Congenital Heart Disease ("CHD") Advancements for 2019
Nov 17, 2019
Mezzion Pharma announces the presentation of the FUEL Trial data at the American Heart Association Meeting in Philadelphia
Nov 04, 2019
Mezzion Pharma announces Top Line Data from FUEL will be presented at the American Heart Association (AHA), Late Breaking Scientific Sessions, in Philadelphia, PA, November 17, 2019
Oct 10, 2019
Mezzion Pharma announces that it has conducted a Type C Meeting with the FDA Regarding the TOP Line Data from the FUEL Phase 3 Clinical Trial
Jul 30, 2019
Mezzion Pharma announces positive results from the Fontan Udenafil Exercise Longitudinal (FUEL) Trial, in adolescents with single ventricle heart disease who have undergone the Fontan procedure
Jun 22, 2018
Mezzion Pharma and NHLBI-Funded Pediatric Heart Network Complete Enrollment in a Pivotal Phase 3 Clinical Trial of Udenafil in Adolescents with Fontan Surgical Palliation - an Orphan Drug Indication
Apr 09, 2018
Mezzion Wins Appellate Jurisdiction Fight Against Dr. Reddy's
Jan 23, 2018
Mezzion Wins Jurisdiction Fight Against Dr. Reddy's In New Jersey State Court